3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
7
Thoracic
3
Gynecologic
3
Genitourinary
3
Gastrointestinal
3
Endocrine
2
Breast
2
Other hematologic neoplasm
1
Dermatologic
1
CNS
1
Conditions
Hematologic Neoplasms
4
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Leukemia
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
tanespimycin
1
pertuzumab
1
entinostat
1
Vorinostat
1
Trastuzumab
1
Thalidomide
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Indinavir
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gene Expression Profiling
1
Flow Cytometry
1
Fentanyl
1
Drug Therapy
1
Docetaxel
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Trastuzumab
×
Other hematologic neoplasm
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled